Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Finke

Showing results (81-90 of 180) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|November 15, 2011
Pruritus in primary myelofibrosis: clinical and laboratory correlatesBrianna E Vaa, Alexandra P Wolanskyj, Lindsey Roeker, et al.
Mayo Clinic Proceedings|April 3, 2008
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patientsAnimesh Pardanani, Terra L Lasho, Kebede Hussein, et al.
Leukemia|October 23, 2009
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patientsA Pardanani, T L Lasho, C M Finke, et al.
Blood Cancer Journal|February 17, 2018
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survivalNatasha Szuber, Christy M Finke, Terra L Lasho, et al.
Blood|January 9, 2010
WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adultsAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
Infection and Immunity|April 1, 1991
Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodiesM Finke, G Muth, T Reichhelm, et al.
Blood Cancer Journal|March 14, 2018
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasmsTerra L Lasho, Rangit Vallapureddy, Christy M Finke, et al.
American Journal of Hematology|April 9, 2015
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemiaMichelle A Elliott, Animesh Pardanani, Curtis A Hanson, et al.
Journal of Neuroinflammation|August 11, 2011
ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsAndrea C Klaver, Mary P Coffey, Lynnae M Smith, et al.
Proteins|February 22, 2011
An accurate model of polyglutamineJyothi L Digambaranath, Tyler V Campbell, Alfred Chung, et al.
Pageof 18

Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|November 15, 2011
Pruritus in primary myelofibrosis: clinical and laboratory correlatesBrianna E Vaa, Alexandra P Wolanskyj, Lindsey Roeker, et al.
Mayo Clinic Proceedings|April 3, 2008
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patientsAnimesh Pardanani, Terra L Lasho, Kebede Hussein, et al.
Leukemia|October 23, 2009
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patientsA Pardanani, T L Lasho, C M Finke, et al.
Blood Cancer Journal|February 17, 2018
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survivalNatasha Szuber, Christy M Finke, Terra L Lasho, et al.
Blood|January 9, 2010
WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adultsAnimesh Pardanani, Ken-Hong Lim, Terra L Lasho, et al.
Infection and Immunity|April 1, 1991
Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodiesM Finke, G Muth, T Reichhelm, et al.
Blood Cancer Journal|March 14, 2018
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasmsTerra L Lasho, Rangit Vallapureddy, Christy M Finke, et al.
American Journal of Hematology|April 9, 2015
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemiaMichelle A Elliott, Animesh Pardanani, Curtis A Hanson, et al.
Journal of Neuroinflammation|August 11, 2011
ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsAndrea C Klaver, Mary P Coffey, Lynnae M Smith, et al.
Proteins|February 22, 2011
An accurate model of polyglutamineJyothi L Digambaranath, Tyler V Campbell, Alfred Chung, et al.
Pageof 18